LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Condition: Non-Small Cell Lung Cancer
Sponsor: NovoCure GmbH
Full Title
EF-44: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
Study Treatment
1:1 randomization between treatment with standard of care chemo and immunotherapy +/- the addition of a Tumor Treatment Fields device.
Eligibility/Info
Stage IV squamous or non-squamous non-small cell lung cancer
No history of systemic therapy for advanced or metastatic non-small cell lung cancer
No targetable oncogenic driver mutations
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
